Objective: To describe clinical features, tomographic findings and pulmonary function in pediatric patients with primary hypogammaglobulinemia (PH). Method: A retrospective cohort study of children with PH who received intravenous immunoglobulin (IVIG) and prophylactic antibiotics between 2005 and 2010. Epidemiological and clinical features, computed tomography (CT) findings, and spirometric data were compared, assuming a 5% significance level.
introduction
Primary hypogammaglobulinemias (PH) are a group of inherited immunodeficiencies, which have in common a deficient production of antibodies. Patients with PH are more susceptible to bacterial infections, especially those caused by encapsulated agents, and the respiratory tract is the most affected site. [1] [2] [3] [4] [5] [6] [7] Clinically, the most important PHs are: agammaglobulinemia (A), common variable immunodeficiency (CVID) and hyper IgM syndrome (HIGMS), characterized by low serum concentrations of immunoglobulins and that benefit from regular replacement of immunoglobulin, showing a decline in the frequency and severity of infections. [8] [9] [10] [11] [12] Even with proper replacement treatment, both international and national studies revealed the presence of bronchiectasis in patients with PH, 5, 6, [13] [14] [15] demonstrating that the decline in infections provided by immunoglobulin replacement does not seem to be enough to prevent the occurrence of pulmonary complications. Chronic pulmonary disease, in particular the development of bron-chiectasis, is one of the most important complications in the evolution of patients, with direct implications regarding their quality of life and mortality. 1, 2, 14, [16] [17] [18] The determinants for the appearance of pulmonary complications are not well established. Understanding the factors that contribute to the development of these complications is highly important for its prevention. The study of pediatric populations can provide key information about the process, and allows the evaluation of the effect of early intervention.
The aim of this study was to describe the clinical characteristics, CT-scan findings and pulmonary function, especially the presence of bronchiectasis, in a group of pediatric patients with PH (A, CVID and HIGMS) receiving intravenous immunoglobulin (IVIG) replacement.
Method
Retrospective cohort study based on data obtained from medical records of patients followed up in the Unit of Allergy and Immunology of Instituto da Criança, HC-FMUSP, between 2005 and 2010.
We included all patients diagnosed with A, CVID or HIGMS according to the criteria of the Pan-American Group for Immunodeficiency/European Society for Immunodeficiencies (PAGID/ESID) 19 who received prophylactic antibiotics (amoxicillin or trimethoprim-sulfamethoxazole) and regular IVIG replacement. The doses and intervals of immunoglobulin therapy were adjusted to obtain serum IgG concentrations of at least 600 mg/ dL immediately before the next infusion.
Demographic and clinical data
The clinical features analyzed were: gender, number and type of infections before and after the diagnosis of immunodeficiency, age at onset of symptoms, age at diagnosis, age at start of treatment, and duration of treatment with immunoglobulin replacement. We defined as "diagnostic delay" the time between symptom onset and the age of diagnosis of the immunodeficiency. We considered as severe pneumonia any pulmonary infection requiring intensive care, endotracheal intubation, hospitalization for treatment with intravenous antibiotics for more than 14 days or the presence of empyema.
Radiological data
Lung imaging studies were performed using computed tomography (CT) of the chest (conventional and high resolution), using axial sections of varying thickness (1.25 to 10 mm) evaluated by the service's radiology specialists. Images taken during or less than 3 months after an acute infection were excluded. For the characterization of the tomographic findings, we included the first and last chest CT scan performed by each patient during follow-up. To assess the severity and extent of lung damage, we applied the Bhalla score. 20 The scale ranges from 0 to 25, with higher values related to the presence of more structural damage to the lungs. The score was applied to the last chest CT by three different pediatric radiologists who were unaware of the patient's medical progression, and the final result was obtained by consensus. 
Evaluation of pulmonary function

Statistical analysis
Statistical analysis was performed using SPSS 13.0 where nominal variables were tested using Fisher's exact test and continuous variables using nonparametric tests (MannWhitney and Kruskal-Wallis). Spearman coefficient was used to relate the Bhalla score with the other variables. All p-values<0.05 were considered statistically significant.
Ethical aspects
The study fulfilled the ethical requirements of the insti- 
results
Thirty patients (21 males) were diagnosed with A (n=14), CVID (n=9) and HIGMS (n=7). Data on gender, age, and the total follow-up time are shown in Table 1 , as well as the age of symptoms onset, age at diagnosis, diagnostic delay, and follow-up time after start of treatment. There was no statistically significant difference between patients with agammaglobulinemia, CVID, and HIGMS in relation to these variables except for gender (male predominance), median total follow-up, and median follow-up time after the start of treatment, which were higher in agammaglobulinemia patients (p=0.025).
Considering that the analyzed groups did not present differences in relation to most findings, comparisons with tomographic findings and spirometry were performed based on the total number of patients (N=30). The median age at onset of symptoms was 8 months (1-96 months) and the median age at diagnosis was 5.8 years (0.6-14.6 years). The median diagnostic delay was 4.7 years (0.2-13 years). The median patient follow-up time was 9.9 years (1.8-17.5 years) and the median age of patients at the time of the last assessment was 16.7 years (4.6-23.4 years).
The beginning of IVIG treatment occurred just after PID diagnosis in 27 patients. In one patient with HIGMS the delay was 3 months, in other with CVID it was 7 months and in another CVID patient was 3.5 years.
The most common clinical manifestations before diagnosis were upper and lower respiratory tract infections. Pneumonia was the most common clinical manifestation before diagnosis, occurring in 24 patients (80%). Considering the total number of patients, the median frequency of pneumonia was 0.6 episodes/patient/year (0-12 episodes/patient/year). After the start of IVIG replacement, the frequency of pneumonia was 0.1 episodes/patient/ year (0-1.7 episodes/patient/year), showing a statistically significant reduction (p<0.001). Before the start of IVIG replacement, severe pneumonia was diagnosed in 12 of 30 patients (40%), with three presenting more than one episode, while after the replacement therapy severe pneumonia occurred in 4 of 30 patients (13.3%), two had one episode and the other two had two episodes each.
All patients underwent at least two chest CT during follow-up and in 11 of them (36%) bronchiectasis were diagnosed in the first scan. Patients with bronchiectasis were older at diagnosis (p=0.001) and had greater delay in diagnosis (p=0.001) than those without bronchiectasis. There was no statistically significant difference in relation to age of symptoms onset or the frequency of pneumonia before the start of treatment ( Table 2 ). Twelve of the 30 patients underwent the first CT scan at diagnosis and six of them presented bronchiectasis at that time.
During follow-up, other seven patients developed bronchiectasis, the last CT scan being performed with a median of 7.2 years after the start of treatment (0.4-16.7 years variation), and, at the end of data collection, 18 of 30 patients had bronchiectasis. There were no statistically significant differences between patients with and without bronchiectasis at the last CT scan in relation to age of onset, age at diagnosis, delay in diagnosis, treatment duration, frequency of pneumonia or occurrence of severe pneumonia before or after the beginning of treatment (Table 3) . In addition to bronchiectasis, 90% (27/30) of patients had other findings, alone or combined, at the last CT scan: bronchial wall thickening (n=16), air trapping (n=12), atelectasis (n=9), mucus plug (n=4), calcified nodules (n=3), bubbles (n=1). The application of the Bhalla score was possible in the last CT scan in only 16 patients. These scans were performed with a median of 7.7 years after the start of IVIG replacement (variation of 1.2-16.4 years). The median score was 11 (range 7-21). Thirteen of 16 patients underwent spirometry in the same year of the last CT scan. These results were correlated with Bhalla score. A statistically significant correlation was found between the score of CT and pre-bronchodilator FEV1 (r=-0.778; p=0.002), post-bronchodilator FEV1 (r=-0.837; p<0.001) and FVC (r=-0.773; p=0.002). A positive correlation between Bhalla score and the number of pneumonias after the start of treatment has been identified in these 16 patients (r=0.561; p=0.024), but no correlation was found between Bhalla score and age at diagnosis, diagnostic delay, number of pneumonias before the start of treatment, and number of severe pneumonia before or after the start of treatment.
discussion
The presence of pulmonary complications in patients with primary hypogammaglobulinemia is often reported in the literature, but few Brazilian studies describe the importance of early diagnosis and prompt treatment for these immunodeficiencies to prevent or minimize long-term complications. The importance of our study was to characterize a group of patients with PH, who received prophylactic antibiotics, and could benefit from early and adequate replacement of immunoglobulin. Also, to identify, in patients with pulmonary changes, what could have been done either based on radiological assessment or spirometry that would anticipate potential interventions.
In recent years, IVIG dosing and administration schedules started to be adjusted individually to maintain IgG trough levels of 600 mg/dL for all patients and above 800 mg/dL for patients with bronchiectasis, in addition to the adjustment based on clinical outcomes. More recently, studies have shown that higher concentrations were correlated with better clinical outcomes. 23 It is important to consider that in our study patients received doses of immunoglobulin for a few years without this individualization, maintaining IgG levels around 500 mg/dL, according to the values recommended by the literature at the time. 8 The maintenance of lower serum IgG levels may explain the development of bronchiectasis in our patients. However, even some patients diagnosed more recently who had appropriate IgG concentrations developed this complication, as reported in the literature, suggesting that other factors must be involved. 3, [24] [25] [26] [27] [28] In this context, our study investigated possible factors related to the development of pulmonary complications in this cohort.
Pneumonia was the most common clinical manifestation before diagnosis in our study group. Furthermore, our study demonstrated the efficacy of immunoglobulin replacement in reducing the frequency and severity of pneumonia in accordance with other studies of patients with PH. [8] [9] [10] [11] [12] 25, [29] [30] [31] [32] Bronchiectasis was the most frequent tomographic finding in this cohort and its early occurrence was associated with older age at diagnosis and greater diagnostic delay. Plebani et al. 3 and Basile et al. 6 have already reported the association between age at diagnosis and the presence of bronchiectasis in patients with agammaglobulinemia, as well as Baris et al., 33 who reported this association for patients with CVID. These data give support to the importance of early diagnosis in the prevention of comorbidities that may compromise patient's quality of life and survival. Awareness of PID as a cause of severe or recurrent pneumonia and active screening of siblings, and other family members of patients with PID, may allow early diagnosis and even the identification of yet asymptomatic patients. 34 Chest CT has been used to assess the presence of pulmonary complications and, in the past, routine CT was encouraged as a monitoring method. However, the risk of repeated exposure to radiation demanded an alternative approach. The Bhalla score, 13 initially proposed for the evaluation of patients with cystic fibrosis, was used to evaluate patients' chest CT due to the absence of a specific score for PID. Subsequently, a tomographic score was developed, but only for patients with CVID. 35 The correlations between Bhalla score and FEV1 and FVC found in our study were also described by Gharagozlou et al. 36 This suggests that the results of spirometry, in addition to clinical evaluation, could help monitoring these patients and that lung function changes could be indicators of the necessity of further investigation.
The positive correlation between the Bhalla score and the number of pneumonia episodes after IVIG replacement found in our study reinforces the need to prevent respiratory infections by maintaining high serum IgG trough levels, antimicrobial prophylaxis, and chest physiotherapy.
The study has limitations especially due to its retrospective design, loss of data and heterogeneity regarding immunoglobulin doses used over the years. Prospective and multicenter studies with more patients could be designed in order to control all variables related to pulmo-nary complications, allowing risk factors assessment using multivariable analysis.
conclusion
In this cohort of patients with primary hypogammaglobulinemia, immunoglobulin replacement combined with the use of prophylactic antibiotics reduced the frequency and severity of lung infections, but did not prevent the development of bronchiectasis and other pulmonary complications.
The association between the development of bronchiectasis and older age at diagnosis as well as diagnostic delay points out the importance of considering the hypothesis of primary immunodeficiency as a differential diagnosis in patients with severe or repeated pneumonia.
Routine pulmonary evaluation is needed for early detection of complications and in this sense, spirometry and clinical evaluation may indicate the need to include imaging methods for detection of morphological abnormalities in the lungs.
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resuMo
Hipogamaglobulinemia primária: o impacto do diagnós-tico precoce nas complicações pulmonares Objetivo: descrever características clínicas, tomográficas e de função pulmonar em pacientes pediátricos com hipogamaglobulinemia primária (HP). Método: estudo de coorte retrospectivo de crianças com HP que recebiam gamaglobulina endovenosa (GEV) e antibiótico profilático entre 2005 e 2010. As características epidemiológicas, clínicas, os achados de tomografia e espirometria foram comparadas adotando níveis de significância de 5%. Resultados: foram avaliados 30 pacientes com HP. Após o início da reposição de GEV, houve redução da frequên-cia de pneumonias (p<0,001). Os 11 pacientes que apresentavam bronquiectasias na primeira tomografia computadorizada (TC) eram mais velhos ao diagnóstico (p=0,001) e tiveram maior atraso no diagnóstico (p=0,001) quando comparados aos pacientes sem bronquiectasias. Ao final do estudo, 18 pacientes apresentavam bronquiectasias e 27/30 também apresentaram outras alterações pulmonares, isoladas ou concomitantes. O escore de Bhalla foi aplicado à última TC de 16/30 pacientes, com mediana do escore de 11 (variação 7-21), com correlação positiva entre o escore e o número de pneumonias após o início do tratamento (r=0,561; p=0,024). O escore foi ainda correlacionado com valores de volume expiratório forçado no primeiro segundo (VEF1) e capacidade vital forçada (CVF) obtidos por espirometria de 13/16 pacientes, com correlação negativa com VEF1 pré-(r=-0,778; p=0,002) e pós-broncodilatador (r=-0,837; p<0,001) e CVF (r=-0,773; p=0,002). Conclusão: complicações pulmonares foram frequentes nesta coorte, apesar da diminuição na frequência de pneumonias com o tratamento. A investigação precoce de pacientes com infecções de repetição para imunodeficiências primárias pode reduzir a frequência dessas complicações. A monitorização de alterações na espirometria pode indicar a necessidade de investigação radiológica.
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